Morgens Waterfall Vintiadis & Co’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Morgens Waterfall Vintiadis & Co’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-20,000	Closed	-$3.12M	–	35
2020 Q2	$3.12M	Buy	20,000 +14,000	+233%	+$2.13M	2.01%	23
2020 Q1	$866K	Sell	6,000 -22,600	-79%	-$4.36M	0.81%	27
2019 Q4	$5.85M	Sell	28,600 -9,400	-25%	-$1.71M	3.97%	4
2019 Q3	$3.05M	Buy	38,000 +3,650	+11%	+$310K	2.34%	22
2019 Q2	$3.24M	Buy	34,350 +2,350	+7%	+$203K	2.23%	23
2019 Q1	$2.73M	Hold	32,000	–	–	1.96%	25
2018 Q4	$1.79M	Hold	32,000	–	–	1.6%	29
2018 Q3	$2.62M	Sell	32,000 -8,000	-20%	-$564K	1.71%	27
2018 Q2	$1.4M	Buy	+40,000	New	+$1.22M	0.99%	31

Other funds holding RETA

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

DFO

Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

PAMU

Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return

Morgens Waterfall Vintiadis & Co's RETA Position: Q3 2020 in Review

Morgens Waterfall Vintiadis & Co sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2020, closing a stake of 20,000 shares — an estimated $3.12M sold.

Morgens Waterfall Vintiadis & Co first reported a position in RETA in Q2 2018 and held it in 9 quarters. The position peaked at $5.85M in Q4 2019. 186 funds tracked by Wall St. Rank hold RETA as of Q3 2020.

Morgens Waterfall Vintiadis & Co reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2020 after selling out during the quarter.
Morgens Waterfall Vintiadis & Co sold 20,000 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2020, an estimated $3.12M.
Morgens Waterfall Vintiadis & Co first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q2 2018 and held it in 9 quarters.
Morgens Waterfall Vintiadis & Co's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $5.85M in Q4 2019.
186 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2020.

Based on Morgens Waterfall Vintiadis & Co's 13F filing for Q3 2020, filed 16 Nov 2020.